Added to YB: 2025-10-10
Pitch date: 2025-10-09
HROW [neutral]
Harrow, Inc.
+15.48%
current return
Author Info
MVC Investing is a long-term investor. BSc in Economics, MSc in Finance. Equity Analyst with a focus on Fundamental Analysis and Valuation. Sign up for the newsletter.
Company Info
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.
Market Cap
$1.6B
Pitch Price
$40.75
Price Target
N/A
Dividend
N/A
EV/EBITDA
38.20
P/E
-324.83
EV/Sales
7.29
Sector
Pharmaceuticals
Category
value
Harrow Hit by Regulatory Noise, Core Thesis Still Holds
HROW (update): Down 7% on CA Board of Pharmacy accusation against compounding unit for quality/compliance issues. Core FDA-approved branded division (main growth driver) unaffected. Compounding represents smaller, declining portion of business. Still undervalued on branded portfolio alone even assigning zero value to compounding division.
Read full article (1 min)